/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

VERRICA PHARMACEUTICALS INC Share Price Today: Live Updates & Key Insights

VERRICA PHARMACEUTICALS INC share price today is $6, up -1.76%. The stock opened at $6.25 against the previous close of $6.26, with an intraday high of $6.51 and low of $5.93.

VERRICA PHARMACEUTICALS INC Share Price Chart

style
pb-0

VERRICA PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

VERRICA PHARMACEUTICALS INC Share Price Performance

$6 -0.0176(-1.76%) VRCA at 13 Mar 2026 03:48 PM Biotechnology
Lowest Today 5.93
Highest Today 6.51
Today’s Open 6.25
Prev. Close 6.26
52 Week High 9.82
52 Week Low 3.28
Day’s Range: Low 5.93 High 6.51
52-Week Range: Low 3.28 High 9.82
1 day return -
1 Week return +16.15
1 month return +6.81
3 month return -19.6
6 month return +22.2
1 year return +933.66
3 year return -6.28
5 year return -64.68
10 year return -

VERRICA PHARMACEUTICALS INC Institutional Holdings

Armistice Capital, LLC 7.00

Caligan Partners LP 5.78

Affinity Asset Advisors, LLC 4.42

Stonepine Capital Management Llc 2.21

BOOTHBAY FUND MANAGEMENT, LLC 1.76

Kalehua Capital Management LLC 1.47

Dafna Capital Management LLC 1.08

Vanguard Group Inc 0.86

Two Sigma Investments LLC 0.74

Millennium Management LLC 0.45

Geode Capital Management, LLC 0.42

Vanguard Institutional Extnd Mkt Idx Tr 0.36

Vanguard Total Stock Mkt Idx Inv 0.33

Two Sigma Advisers, LLC 0.28

UBS Group AG 0.26

Squarepoint Ops LLC 0.21

Sovran Advisors, LLC 0.20

Fidelity Extended Market Index 0.18

Renaissance Technologies Corp 0.17

Mariner Wealth Advisors LLC 0.15

Omers Administration Corp 0.14

Morgan Stanley - Brokerage Accounts 0.14

State Street Corp 0.13

Bridgeway Ultra-Small Company Market 0.08

Fidelity Total Market Index 0.07

Fidelity Series Total Market Index 0.06

Spartan Extended Market Index Pool F 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

NT Ext Equity Mkt Idx Fd - NL 0.04

Fidelity Nasdaq Composite Index 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Blackrock Extended Mkt Fund CF 0.03

Spartan Total Market Index Pool G 0.03

Extended Equity Market Fund K 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

PGIM US Micro Cap Quant Equity 0.02

Northern Small Cap Core I 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

State St US Extended Mkt Indx NL Cl C 0.00

VERRICA PHARMACEUTICALS INC Market Status

Strong Buy: 2

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

VERRICA PHARMACEUTICALS INC Fundamentals

Market Cap 100.10 M

PB Ratio 238.5425

PE Ratio 0.0

Enterprise Value 114.74 M

Total Assets 47.13 M

Volume 171048

VERRICA PHARMACEUTICALS INC Company Financials

Annual Revenue FY23:3204000 3.2M, FY22:9032000 9.0M, FY21:12000000 12.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:2668000 2.7M, FY22:8307000 8.3M, FY21:12000000 12.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-48313000 -48.3M, FY22:-27678000 -27.7M, FY21:-38903000 -38.9M, FY20:-45497000 -45.5M, FY19:-27950000 -28.0M

Quarterly Revenue Q3/2025:14344000 14.3M, Q2/2025:12702000 12.7M, Q1/2025:3439000 3.4M, Q3/2024:-1781000 -1.8M, Q2/2024:5177000 5.2M

Quarterly Profit Q3/2025:13235000 13.2M, Q2/2025:12362000 12.4M, Q1/2025:3016000 3.0M, Q3/2024:-2216000 -2.2M, Q2/2024:4635000 4.6M

Quarterly Net worth Q3/2025:-274000 -0.3M, Q2/2025:204000 0.2M, Q1/2025:-9742000 -9.7M, Q3/2024:-22860000 -22.9M, Q2/2024:-17186000 -17.2M

About VERRICA PHARMACEUTICALS INC & investment objective

Company Information Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Organisation Biotechnology

Employees 71

Industry Biotechnology

CEO Dr. Jayson M. Rieger M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow